Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting.

"Transparency declaration P.K. and A.W. are employees of MSD Sharp and Dohme GmbH. S.T. has no conflicts to declare. C.B. has received honoraria from Pfizer. O.A.C. has received research funding from Astellas, Basilea, Gilead, Pfizer, MSD Sharp and Dohme/Merck&Co., Schering-Plough, and Vicuron; is a consultant to Astellas, Basilea, Gilead, Pfizer, MSD Sharp and Dohme/Merck&Co., Nektar, Schering-Plough, and Zeneus; and served at the speaker’s bureau of Astellas, Gilead, MSD Sharp and Dohme/Merck&Co., and Schering-Plough. A.G. has received research funding from Janssen-Cilag/Ortho Biotech, MSD Sharp and Dohme/Merck&Co., and Pfizer, is a consultant to Janssen-Cilag/Ortho Biotech, MSD Sharp and Dohme, Pfizer and Schering-Plough/ Essex Pharma, and has received speaker’s honoraria from Gilead, Janssen-Cilag/Ortho-Biotech, MSD Sharp and Dohme/ Merck&Co., and Pfizer. H.P.L. has received honoraria from Gilead, MSD Sharp and Dohme, and Essex Pharma/Schering-Plough. A.J.U. has received research funding from Schering-Plough; has been a consultant for Astellas, Basilea, Gilead, MSD Sharp and Dohme/Merck&Co., Pfizer, and Schering-Plough; and has been a member of the speakers’ bureaus of Astellas, Gilead, MSD Sharp and Dohme/ Merck&Co., Pfizer, and Schering-Plough."